FIELD: medicine.
SUBSTANCE: compound has structure: 5'ugaagggugaaauauucuc-Z3' 3'Z'-acuucccacuuuauaagag5', where constituting it ribonucleotides can be both 2'-O-Me-modified by sugar residue and non-modified. A Z and Z', if present, means dTdT, which is covalently bound on 3'- chain end. Claimed invention also relates to pharmaceutical composition, containing claimed compound and pharmaceutically acceptable carrier. Obtained compound or pharmaceutical composition can be used for treatment of patient with acute renal failure or ischemic-reperfusion injury, caused by surgery, or for treatment of patient with induced by cisplatin deafness.
EFFECT: introduction of claimed compound contributes to improvement of transplanted tissue survival after transplantation in patient.
18 cl, 7 dwg, 5 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| OLIGORIBONUCLEOTIDES AND METHODS OF THEIR APPLICATION FOR TREATMENT OF ACUTE RENAL FAILURE | 2005 |
|
RU2584609C2 |
| HSP47 EXPRESSION MODULATION | 2010 |
|
RU2575056C2 |
| TREATMENT OF CNS DISORDERS | 2007 |
|
RU2426544C2 |
| TREATMENT OF DISEASES ASSOCIATED WITH ERYTHROPOIETIN (EPO) BY NATURAL EPO ANTISENSE TRANSCRIPT INHIBITION | 2009 |
|
RU2620970C2 |
| TREATMENT OF INTESTINAL DISEASES | 2006 |
|
RU2418594C2 |
| LIPOSOMS WITH RETYNOID TO STRENGTHEN hsp47 EXPRESSION MODULATION | 2012 |
|
RU2628694C2 |
| TREATMENT OF TUMORS OF DISEASES RELATED TO THE GENOM-SUPPRESSOR BY THERAPY OF NATURAL TRANSCRIPT INHIBITION IN ANTI-SIGNIFICANT ORIENTATION REGARDING THIS GENE | 2009 |
|
RU2618688C2 |
| MEDIATED PHKi INHIBITION OF Rho-KINASE FOR TREATING OPHTHALMIC DISORDERS | 2006 |
|
RU2432165C2 |
| TREATMENT OF TUMORS OF DISEASES RELATED TO THE GENOM-SUPPRESSOR BY THERAPY OF NATURAL TRANSCRIPT INHIBITION IN ANTI-SIGNIFICANT ORIENTATION REGARDING THIS GENE | 2009 |
|
RU2746478C2 |
| METHODS FOR TREATMENT OF HEPATITIS B INFECTION | 2018 |
|
RU2780021C2 |
